The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
April 29th 2025
A 15-mg dose with a corticosteroid taper regimen was superior to placebo in sustained remission from week 12 to 52.
Regulatory Committee Advises Against Approval of Actavis' Hypertension Treatment
September 11th 2014The FDA's Cardiovascular and Renal Drugs Advisory Committee has recommended against the approval of Actavis' fixed-dose combination of nebivolol and valsartan for the treatment of hypertension.
Read More